JP2019533690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533690A5 JP2019533690A5 JP2019522771A JP2019522771A JP2019533690A5 JP 2019533690 A5 JP2019533690 A5 JP 2019533690A5 JP 2019522771 A JP2019522771 A JP 2019522771A JP 2019522771 A JP2019522771 A JP 2019522771A JP 2019533690 A5 JP2019533690 A5 JP 2019533690A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- arenavirus
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022188395A JP2023029898A (ja) | 2016-11-04 | 2022-11-25 | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417865P | 2016-11-04 | 2016-11-04 | |
| US201662417891P | 2016-11-04 | 2016-11-04 | |
| US62/417,865 | 2016-11-04 | ||
| US62/417,891 | 2016-11-04 | ||
| PCT/EP2017/078149 WO2018083220A2 (en) | 2016-11-04 | 2017-11-03 | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188395A Division JP2023029898A (ja) | 2016-11-04 | 2022-11-25 | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533690A JP2019533690A (ja) | 2019-11-21 |
| JP2019533690A5 true JP2019533690A5 (https=) | 2020-12-17 |
Family
ID=60452580
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522771A Withdrawn JP2019533690A (ja) | 2016-11-04 | 2017-11-03 | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
| JP2022188395A Pending JP2023029898A (ja) | 2016-11-04 | 2022-11-25 | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188395A Pending JP2023029898A (ja) | 2016-11-04 | 2022-11-25 | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200206334A1 (https=) |
| EP (1) | EP3534943A2 (https=) |
| JP (2) | JP2019533690A (https=) |
| CN (1) | CN110167586B (https=) |
| AU (1) | AU2017353443B2 (https=) |
| CA (1) | CA3039356A1 (https=) |
| WO (1) | WO2018083220A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| CN115058452A (zh) | 2013-12-03 | 2022-09-16 | 霍欧奇帕生物科技有限公司 | Cmv疫苗 |
| LT3218504T (lt) | 2014-11-13 | 2020-09-10 | Université De Geneve | Trijų segmentų arenavirusai kaip vakcinos vektoriai |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| IL314371A (en) | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| RS63546B1 (sr) | 2015-11-12 | 2022-09-30 | Hookipa Biotech Gmbh | Čestice arenavirusa kao vakcine protiv kancera |
| JP2020514321A (ja) | 2017-02-01 | 2020-05-21 | モデルナティーエックス， インコーポレイテッド | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| AU2018247958A1 (en) * | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| CN117280027A (zh) | 2021-03-23 | 2023-12-22 | 霍欧奇帕生物科技有限公司 | 用于治疗前列腺癌的沙粒病毒 |
| CA3236106A1 (en) * | 2021-11-08 | 2023-05-11 | Henning Lauterbach | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| CN115058452A (zh) | 2013-12-03 | 2022-09-16 | 霍欧奇帕生物科技有限公司 | Cmv疫苗 |
| LT3218504T (lt) * | 2014-11-13 | 2020-09-10 | Université De Geneve | Trijų segmentų arenavirusai kaip vakcinos vektoriai |
| EP3307308A2 (en) * | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
-
2017
- 2017-11-03 EP EP17804079.6A patent/EP3534943A2/en active Pending
- 2017-11-03 AU AU2017353443A patent/AU2017353443B2/en active Active
- 2017-11-03 CA CA3039356A patent/CA3039356A1/en active Pending
- 2017-11-03 WO PCT/EP2017/078149 patent/WO2018083220A2/en not_active Ceased
- 2017-11-03 JP JP2019522771A patent/JP2019533690A/ja not_active Withdrawn
- 2017-11-03 US US16/347,501 patent/US20200206334A1/en not_active Abandoned
- 2017-11-03 CN CN201780080962.4A patent/CN110167586B/zh active Active
-
2022
- 2022-11-25 JP JP2022188395A patent/JP2023029898A/ja active Pending
-
2024
- 2024-05-08 US US18/658,403 patent/US20250009860A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533690A5 (https=) | ||
| JP2023029898A5 (https=) | ||
| JP7506030B2 (ja) | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ | |
| JP7157662B2 (ja) | 癌ワクチンとしてのアレナウイルス粒子 | |
| JP2023029898A (ja) | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 | |
| JP2018533604A5 (https=) | ||
| TWI780069B (zh) | 用於病毒專一性t細胞之活化及增生的平台 | |
| US20200113995A1 (en) | Arenavirus particles to treat solid tumors | |
| EP4141111A1 (en) | Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells | |
| JP2020516601A5 (https=) | ||
| JP7781511B2 (ja) | Ｔｅｒｔ免疫原性組成物及びそれを用いた治療方法 | |
| JPWO2017209053A1 (ja) | 新規な遺伝子組換えワクシニアウイルス | |
| WO2022188764A1 (zh) | 一种低表达cd7的nk细胞制备方法 | |
| AU2013204923A1 (en) | Modified t lymphocytes having improved specificity | |
| CA2575591A1 (en) | A pharmaceutical composition for treatment of cancers | |
| US12558417B2 (en) | Hepatitis A virus preparation method and hepatitis A virus prepared according to method | |
| WO2025131084A1 (en) | Use of dr-18 and m1 virus in preparation of anti-tumor drug | |
| US20240245765A1 (en) | Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines | |
| Guinn et al. | International society for cell and gene therapy of cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers | |
| Weigel-Van Aken | Cancer Gene Therapy | |
| HK1260579B (en) | Arenavirus particles as cancer vaccines | |
| HK1260579A1 (en) | Arenavirus particles as cancer vaccines |